New stock news | It is rumored that the Chinese surgical robotics company "Jingfeng Medical" has secretly applied to go public in Hong Kong, aiming to raise approximately 1.5 to 2 billion US dollars.

According to media reports, the Chinese surgical robotics company Jingfeng Medical, supported by Temasek in Singapore, has secretly applied to go public in Hong Kong, hoping to list as early as this year, raising approximately $150-200 million. Jingfeng Medical has appointed GF SEC and Morgan Stanley to handle the IPO, with details such as the size and timing of the IPO still to be determined. Jingfeng Medical previously applied for a listing in Hong Kong in 2022 and 2023. The company was founded in 2017 by two joint doctoral graduates from MIT and Harvard University, Wang Jianchen and Gao Yuanqian. It is the first and the second company in the world to have products of surgical robots with multiple pores, single pores, and bronchoscopy. After completing a cross-round financing in December 2021, its valuation exceeded $1.5 billion (equivalent to about 10.6 billion RMB). Jingfeng Medical's core products include the Siasun Robot & Automation MP1000 for multi-port endoscopy surgery, the Siasun Robot & Automation SP1000 for single-port endoscopy surgery, and the Siasun Robot & Automation CP1000 for natural orifice surgery. The MP1000 completed a registered clinical trial for urological surgery in December 2021, and submitted a registration application to the National Medical Products Administration (NMPA) in January 2022. The clinical trial, led by a well-known academician, demonstrated excellent efficacy and safety. As of August 2023, the MP1000 has been approved for application in all departments.